Phase 3 N=77 Homeopathic Treatment of Post-acute COVID-19 Syndrome
Post-acute Covid-19 Syndrome
Primary: Fatigue Assessment Scale (FAS) — 32.9; 31.4; 29.0; 27.4 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)
Covid19
Primary: Insulin-Like Growth Factor-1 (IGF1) — 142.8; 137.6 ng/ml
N/A N=21 Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention
Long COVID
Primary: Change in Functional Improvement Post-COVID-19 Over Time — 8.4; 21.05; 4.55; 6.6 score on a scale — p=.06
N/A N=64 Cognitive Rehabilitation in Post-COVID-19 Syndrome
Post-COVID-19 Syndrome
Primary: Recruitment Rate — 65 Participants
N/A N=20 CoV-PICS: A Virtual Post-ICU Clinic
Post ICU Syndrome
Primary: Acceptance With COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Visits - AIM — 4.8 score on a scale
N/A N=18 Vagal Nerve Stimulation for Post COVID Fatigue
Post COVID Syndrome · Fatigue · Headache
Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Phase 2 N=18 Dual MRI for Cardiopulmonary COVID-19 Long Haulers
Covid19
Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)
Phase 2 N=155 Paxlovid for Treatment of Long Covid
Post-acute Sequelae of SARS-CoV-2 Infection · Long COVID
Primary: Number of Participants With No, Mild, Moderate, or Severe Symptoms at Week 10 According to the Core Symptoms Severity Scale Score — 3; 4; 22; 17 Participants — p=0.903
Phase 2 N=80 Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
Post COVID-19 Condition · Long COVID
Primary: Change From Baseline to Week 13 in PROMIS Fatigue Score (T-Score) — 69.9; 69.4; -25.4; -25.8 T-Score — p=0.9851
Phase 2 N=963 RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms
Long COVID · Long Covid19
Primary: Total Number of Participants Enrolled in Each Appendix — 323; 320; 320 Participants
Phase 2 N=79 Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome
Post COVID-19 Syndrome
Primary: Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Extreme Fatigue (ANCOVA Model) — -2.376; -2.430 score on a scale (10 points total) — p=0.9416
N/A N=328 RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms
Long COVID · Long COVID-19 · Long COVID19
Primary: Total Number of Participants Enrolled in Each Appendix — 64; 67; 66; 66 Participants
N/A N=182 Telerehabilitation in People With Long COVID
COVID-19
Primary: Change in Exercise Capacity: Peak Oxygen Uptake (VO2peak) From Baseline to 12 Weeks — 2.4; 1.7 ml/kg/min
Phase 2 N=53 Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
Postural Orthostatic Tachycardia Syndrome
Primary: Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version) — -14.369; -15.957 score on a scale
N/A N=74 Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue
Post Covid-19 Patients
Primary: Fatigue Assessment Scale (FAS) — 31.32; 28.42; 14.90; 15.3 Total score (1 to 5 point scale)
Phase 2 N=34 Extension Study in a Cohort of Adult Patients With COVID-19 Infection
COVID-19 Infection
Primary: Number and Percentage of Participants With Complications Related to Post COVID-19 Infection — 4; 8; 5; 17 Participants
Phase 2 N=963 RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms
Long COVID-19 · Long COVID
Primary: Percentage of Participants Who Improved in Cognitive Dysfunction Symptom Cluster, as Measured by Patient-Reported Outcomes Measurement Information System (PROMIS)…
N/A N=28 Balance Function in Patients Post Corona Virus Disease 2019 (COVID-19)
Covid19
Primary: Motor Balance as Measured by Timed Up and Go (TUG) — 20.57 seconds
Phase 3 N=22 Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.
Long COVID
Primary: Change in the Symptoms of Long COVID-19 Patients — 20.33; 27; 15.71; 22.43 units on a scale — p=0.200
Phase 3 N=72 Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
Traumatic Brain Injury · Fatigue · Cognitive Impairment
Primary: Lean Body Mass as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline — 49.9; 49.6 kilograms
N/A N=44 Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors
Covid-19 · Deconditioning
Primary: Adherence (Primary Feasibility/Safety Outcome) — 93 % of participants meeting adherence
Phase 2 N=19 Electrical Stimulation for Critically Ill Post-Covid-19 Patients
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
N/A N=47 Chronic-disease Self-management Program in Patients Living With Long-COVID in Puerto Rico
Long Covid19
Primary: Assessment of the Impact of Health-related Quality of Life — 4; 3; 4; 6 Participants
Phase 3 N=676 Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia.
Post-acute COVID-19 Syndrome
Primary: Change in the Mean FSS Score. — 46.4; 45.9; 29.9; 31.9 score on a scale — p=0.0016
N/A N=252 Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic
Covid19 · Critical Care · Postintensive Care Syndrome
Primary: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) — 5; 13.5 units on a scale
N/A N=30 Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Postacute Sequelae of Sars-CoV-2
Postacute Sequelae of Sars-CoV-2 · Post-Acute COVID-19 Syndrome · Widespread Chronic Pain
Primary: Mean Change in Functional Interference From Pain From Baseline to 4 Weeks (Blinded Phase) — 0.454; 0.198 score on a scale
N/A N=119 Myocardial Injury and Quality of Life After COVID-19
COVID-19 · Myocardial Injury · Myocarditis Post Infection
Primary: Percentage of Patients (%) Recovered From COVID-19 With a Decrease in the Global Contractility of the Left and Right Ventricles. — 19; 39; 48 Participants
Phase 2 N=149 Vortioxetine for Post-COVID-19 Condition
Post-COVID-19 Condition · Post-COVID-19 Syndrome · Cognitive Impairment
Primary: Least Square Mean Change in Baseline to Week 8 on Z-score in Combined Digit Symbol Substitution Test (DSST) — 0.332; 0.184 score on a scale
N/A N=17 Vagus Nerve Stimulation as Treatment for Long Covid
Long COVID · Chronic Fatigue Syndrome
Primary: Number of Participants With Treatment Success — 8 Participants
N/A N=44 Swallowing Impairment After COVID-19 Infection
Covid19
Primary: Number of Participants With Impaired Swallowing Safety — 3; 1 Participants — p=<0.001